Back to top
more

Integer Holdings (ITGR)

(Real Time Quote from BATS)

$132.65 USD

132.65
41,729

+0.22 (0.17%)

Updated Oct 15, 2024 02:07 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Patterson Companies (PDCO) Partners With Pearl for AI Services

by Zacks Equity Research

Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.

Are You Looking for a Top Momentum Pick? Why Integer (ITGR) is a Great Choice

by Zacks Equity Research

Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.

Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.

Why You Should Add Integer Holdings (ITGR) to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.

McKesson (MCK) Announces Availability of FDA-Cleared mCRC Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.

New Strong Buy Stocks for November 17th

by Zacks Equity Research

DDL, FINW, SCS, PGR and ITGR have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2023.

Best Value Stocks to Buy for November 17th

by Zacks Equity Research

FMN, SCS and ITGR made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 17, 2023.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

by Zacks Equity Research

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite

by Zacks Equity Research

Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Charles River (CRL) to Advance AI Drug Discovery With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

by Zacks Equity Research

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Veradigm's (MDRX) New Offering to Enhance Patient Engagement

by Zacks Equity Research

Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.

Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.

Zacks.com featured highlights Oshkosh, Everest Group, Leidos, Itron and Integer

by Zacks Equity Research

Oshkosh, Everest Group, Leidos, Itron and Integer have been highlighted in this Screen of The Week article.

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.